Zehan Chen

1.7k citations

31 papers · 1.3k · h-index 17

Impact in

Oncology top 5%
- Cancer-related Molecular Pathways
- PARP inhibition in cancer therapy
Molecular Biology top 10%
- DNA Repair Mechanisms
- Cancer therapeutics and mechanisms
- Cell death mechanisms and regulation

Papers in

Molecular Biology 19
- DNA Repair Mechanisms 14
- Cancer therapeutics and mechanisms 9
- Ubiquitin and proteasome pathways 2
- Cell death mechanisms and regulation 2
Oncology 16
- Cancer-related Molecular Pathways 15

Co-authors: Saul H. Rosenberg (17 shared papers)Thomas J. Sowin (13 shared papers)Haiying Zhang (14 shared papers)Zhan Xiao (5 shared papers)Angelo Gunasekera (1 shared paper)Peter Kovar (15 shared papers)Hing L. Sham (11 shared papers)Nan‐Horng Lin (13 shared papers)
Journals: Bioorganic & Medicinal Chemistry Letters (8 papers)Journal of Medicinal Chemistry (2 papers)Neoplasia (2 papers)Journal of Biological Chemistry (2 papers)Molecular Cancer Therapeutics (1 paper)
Partner nations: United States China United Kingdom

In The Last Decade

Zehan Chen

28 papers receiving 1.3k citations

Peers

Countries citing papers authored by Zehan Chen

Since Specialization

Citations

This map shows the geographic impact of Zehan Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zehan Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zehan Chen more than expected).

Fields of papers citing papers by Zehan Chen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zehan Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zehan Chen. The network helps show where Zehan Chen may publish in the future.

Co-authors

The 25 scholars most cited alongside Zehan Chen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Zehan Chen Line = papers co-authored together Zehan Chen links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 31 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Chk1 Mediates S and G2 Arrests through Cdc25A Degradation in Response to DNA-damaging Agents Journal of Biological Chemistry ·Zhan Xiao, Zehan Chen, Angelo Gunasekera, Thomas J. Sowin, Saul H. Rosenberg, Steve Fesik, Haiying Zhang	2003	298
2	NMR structure and mutagenesis of the FADD (Mort1) death-effector domain Nature ·Matthias Eberstadt, Baohua Huang, Zehan Chen, Robert Meadows, Shi-Chung Ng, Lixin Zheng, Michael J. Lenardo, Stephen W. Fesik	1998	216
3	Selective Chk1 inhibitors differentially sensitize p53‐deficient cancer cells to cancer therapeutics International Journal of Cancer ·Zehan Chen, Zhan Xiao, Wen‐Zhen Gu, John Xue, Mai H. Bui, Peter Kovar, Gaoquan Li, Gary Wang, Zhi‐Fu Tao, Yunsong Tong, Nan‐Horng Lin, Hing L. Sham, Jean Y. J. Wang, Thomas J. Sowin, Saul H. Rosenberg, Haiying Zhang	2006	107
4	1-Benzyl-3-cetyl-2-methylimidazolium iodide (NH125) Induces Phosphorylation of Eukaryotic Elongation Factor-2 (eEF2) Journal of Biological Chemistry ·Zehan Chen, Sujatha M. Gopalakrishnan, Mai-Ha Bui, Niru B. Soni, Usha Warrior, Eric F. Johnson, Jennifer B. Donnelly, Keith B. Glaser	2011	96
5	Human Chk1 expression is dispensable for somatic cell death and critical for sustaining G2 DNA damage checkpoint. PubMed ·Zehan Chen, Zhan Xiao, Jun Chen, Shi‐Chung Ng, Thomas J. Sowin, Hing L. Sham, Saul H. Rosenberg, Steve Fesik, Haiying Zhang	2003	84
6	Structure-Based Design, Synthesis, and Biological Evaluation of Potent and Selective Macrocyclic Checkpoint Kinase 1 Inhibitors Journal of Medicinal Chemistry ·Zhi‐Fu Tao, Le Wang, Kent D. Stewart, Zehan Chen, Wendy Gu, Mai-Ha Bui, Philip J. Merta, Haiying Zhang, Peter Kovar, Eric F. Johnson, Chang Park, Russell A. Judge, Saul H. Rosenberg, Thomas J. Sowin, Nan‐Horng Lin	2007	72
7	Platelet-rich plasma versus hyaluronic acid in the treatment of knee osteoarthritis Medicine ·Zehan Chen, Chang Wang, Di You, Shishun Zhao, Zhe Zhu, Meng Xu	2020	55
8	Blocking CHK1 Expression Induces Apoptosis and Abrogates the G2 Checkpoint Mechanism Neoplasia ·Yan Luo, Shayna K. Rockow-Magnone, Paul E. Kroeger, Leigh Frost, Zehan Chen, Edward K. Han, Shi‐Chung Ng, Robert L. Simmer, Vincent L. Giranda	2001	43
9	Downregulation of Akt1 Inhibits Anchorage-Independent Cell Growth and Induces Apoptosis in Cancer Cells Neoplasia ·Xuesong Liu, Yan Shi, Edward K. Han, Zehan Chen, Saul H. Rosenberg, Vincent L. Giranda, Yan Luo, Shi‐Chung Ng	2001	41
10	Synthesis and biological evaluation of 3-ethylidene-1,3-dihydro-indol-2-ones as novel checkpoint 1 inhibitors Bioorganic & Medicinal Chemistry Letters ·Nan‐Horng Lin, Ping Xia, Peter Kovar, Chang Park, Zehan Chen, Haiying Zhang, Saul H. Rosenberg, Hing L. Sham	2005	38
11	1-(5-Chloro-2-alkoxyphenyl)-3-(5-cyano- pyrazi-2-yl)ureas as Potent and Selective Inhibitors of Chk1 Kinase: Synthesis, Preliminary SAR, and Biological Activities Journal of Medicinal Chemistry ·Gary T. Wang, Gaoquan Li, Robert A. Mantei, Zehan Chen, Peter Kovar, Wendy Gu, Zhan Xiao, Haiying Zhang, Hing L. Sham, Thomas J. Sowin, Saul H. Rosenberg, Nan‐Horng Lin	2005	37
12	A-432411, a novel indolinone compound that disrupts spindle pole formation and inhibits human cancer cell growth Molecular Cancer Therapeutics ·Zehan Chen, Philip J. Merta, Nan-Hong Lin, Stephen K. Tahir, Peter Kovar, Hing L. Sham, Haiying Zhang	2005	36
13	Discovery of 1,4-dihydroindeno[1,2-c]pyrazoles as a novel class of potent and selective checkpoint kinase 1 inhibitors Bioorganic & Medicinal Chemistry ·Yunsong Tong, Akiyo Claiborne, Kent D. Stewart, Chang Park, Peter Kovar, Zehan Chen, R.B. Credo, Wen‐Zhen Gu, Stephen L. Gwaltney, Russell A. Judge, Haiying Zhang, Saul H. Rosenberg, Hing L. Sham, Thomas J. Sowin, Nan‐Horng Lin	2007	33
14	Synthesis and biological evaluation of 1-(2,4,5-trisubstituted phenyl)-3-(5-cyanopyrazin-2-yl)ureas as potent Chk1 kinase inhibitors Bioorganic & Medicinal Chemistry Letters ·Gaoquan Li, Lisa Hasvold, Zhi‐Fu Tao, Gary T. Wang, Stephen L. Gwaltney, Jyoti Patel, Peter Kovar, R.B. Credo, Zehan Chen, Haiying Zhang, Chang Park, Hing L. Sham, Thomas J. Sowin, Saul H. Rosenberg, Nan‐Horng Lin	2006	29
15	Discovery of 4′-(1,4-dihydro-indeno[1,2-c]pyrazol-3-yl)-benzonitriles and 4′-(1,4-dihydro-indeno[1,2-c]pyrazol-3-yl)-pyridine-2′-carbonitriles as potent checkpoint kinase 1 (Chk1) inhibitors Bioorganic & Medicinal Chemistry Letters ·Zhi‐Fu Tao, Gaoquan Li, Yunsong Tong, Kent D. Stewart, Zehan Chen, Mai-Ha Bui, Philip J. Merta, Chang Park, Peter Kovar, Haiying Zhang, Hing L. Sham, Saul H. Rosenberg, Thomas J. Sowin, Nan‐Horng Lin	2007	25
16	Kinase Drug Discovery by Affinity Selection/Mass Spectrometry (ASMS): Application to DNA Damage Checkpoint Kinase Chk1 SLAS DISCOVERY ·Kenneth M. Comess, Jonathan D. Trumbull, Chang Park, Zehan Chen, Russell A. Judge, Martin J. Voorbach, Michael Coen, Lan Gao, Hua Tang, Peter Kovar, Xueheng Cheng, Mark E. Schurdak, Haiying Zhang, Tom Sowin, David J. Burns	2006	25
17	Synthesis and biological evaluation of 4′-(6,7-disubstituted-2,4-dihydro-indeno[1,2-c]pyrazol-3-yl)-biphenyl-4-ol as potent Chk1 inhibitors Bioorganic & Medicinal Chemistry Letters ·Zhi‐Fu Tao, Gaoquan Li, Yunsong Tong, Zehan Chen, Philip J. Merta, Peter Kovar, Haiying Zhang, Saul H. Rosenberg, Hing L. Sham, Thomas J. Sowin, Nan‐Horng Lin	2007	22
18	Macrocyclic ureas as potent and selective Chk1 inhibitors: An improved synthesis, kinome profiling, structure–activity relationships, and preliminary pharmacokinetics Bioorganic & Medicinal Chemistry Letters ·Zhi‐Fu Tao, Zehan Chen, Mai-Ha Bui, Peter Kovar, Eric F. Johnson, Jennifer J. Bouska, Haiying Zhang, Saul H. Rosenberg, Thomas J. Sowin, Nan‐Horng Lin	2007	14
19	Investigation of novel 7,8-disubstituted-5,10-dihydro-dibenzo[b,e][1,4]diazepin-11-ones as potent Chk1 inhibitors Bioorganic & Medicinal Chemistry Letters ·Lisa Hasvold, Le Wang, Magdalena Przytulinska, Zhan Xiao, Zehan Chen, Wen‐Zhen Gu, Philip J. Merta, John Xue, Peter Kovar, Haiying Zhang, Chang Park, Thomas J. Sowin, Saul H. Rosenberg, Nan‐Horng Lin	2008	13
20	Synergistic effect of paclitaxel and 4-hydroxytamoxifen on estrogen receptor-negative colon cancer and lung cancer cell lines Anti-Cancer Drugs ·Wen‐Zhen Gu, Zehan Chen, Stephen K Tahir, Saul H. Rosenberg, Shi-Chung Ng	1999	13

About Zehan Chen

Zehan Chen is a scholar working on Molecular Biology, Oncology, Cell Biology, Computer Vision and Pattern Recognition and Organic Chemistry, having authored 31 papers that have together received 1.3k indexed citations. Recurring topics across this work include Cancer-related Molecular Pathways (15 papers), DNA Repair Mechanisms (14 papers), Cancer therapeutics and mechanisms (9 papers), Microtubule and mitosis dynamics (5 papers), Ubiquitin and proteasome pathways (2 papers), Cell death mechanisms and regulation (2 papers), Network Security and Intrusion Detection (2 papers) and Cancer Mechanisms and Therapy (2 papers). The work is most often cited by research in Oncology (417 citations), Molecular Biology (1.0k citations), Cell Biology (185 citations), Toxicology (30 citations) and Cancer Research (120 citations). Zehan Chen has collaborated with scholars based in United States, China and United Kingdom. Frequent co-authors include Saul H. Rosenberg, Thomas J. Sowin, Haiying Zhang, Zhan Xiao, Angelo Gunasekera, Peter Kovar, Hing L. Sham, Nan‐Horng Lin, Robert Meadows and Baohua Huang. Their work appears in journals such as Bioorganic & Medicinal Chemistry Letters, Journal of Medicinal Chemistry, Neoplasia, Journal of Biological Chemistry and Molecular Cancer Therapeutics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Zehan Chen

Impact in

Papers in i

In The Last Decade

Zehan Chen

Peers

Countries citing papers authored by Zehan Chen

Fields of papers citing papers by Zehan Chen

All Works

About Zehan Chen

Explore authors with similar magnitude of impact

Papers in